Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Recro Pharma, Inc. | reph-ex321_9.htm |
| EX-31.3 - EX-31.3 - Recro Pharma, Inc. | reph-ex313_101.htm |
| EX-31.2 - EX-31.2 - Recro Pharma, Inc. | reph-ex312_15.htm |
| EX-31.1 - EX-31.1 - Recro Pharma, Inc. | reph-ex311_17.htm |
| EX-21.1 - EX-21.1 - Recro Pharma, Inc. | reph-ex211_12.htm |
| EX-10.38 - EX-10.38 - Recro Pharma, Inc. | reph-ex1038_282.htm |
| EX-10.20 - EX-10.20 - Recro Pharma, Inc. | reph-ex1020_281.htm |
| EX-5.1 - EX-5.1 - Recro Pharma, Inc. | reph-ex51_283.htm |
| EX-4.8 - EX-4.8 - Recro Pharma, Inc. | reph-ex48_284.htm |
| 10-K - 10-K - Recro Pharma, Inc. | reph-10k_20171231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Recro Pharma Inc.:
We consent to the incorporation by reference in the Registration Statements (No. 333-216581, 333-216579, 333-208750, 333-208749, 333-206309, and 333-194730) on Form S-8, (No. 333-206492 and 333-218487) on Form S-3, and (No. 333-201841) on Form S-1 of Recro Pharma, Inc. of our report dated March 2, 2018, with respect to the consolidated balance sheets of Recro Pharma, Inc. and subsidiaries as of December 31, 2017 and 2016, and the related consolidated statements of operations and comprehensive income (loss), shareholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2017, and the related notes (collectively, the "consolidated financial statements”), which report appears in the December 31, 2017 annual report on Form 10-K of Recro Pharma, Inc.
|
/s/ KPMG LLP |
|
|
|
Philadelphia, Pennsylvania |
|
March 2, 2018 |